• Call Us +972 (0)4 - 828 8500
  • Email Carmel@univ.haifa.ac.il

MemoDero Ltd.

Developing a first-in-class drug candidate to prevent debilitating consequences of fear-related diseases such as posttraumatic stress disorder (PTSD).


Company Background
MemoDero Ltd. was founded in 2015 by Carmel - the University of Haifa’s economic corporation, based on the development of a pharmaceutical drug for the treatment of fear and stress-related disorders.
The company’s research is spearheaded by Prof. Raphael (Rafi) Lamprecht and Dr. Monica Dines from the University of Haifa. The team is currently in the advanced stages of developing and evaluating the drug, pep-EphrinA4, aimed at reducing or preventing the debilitating consequences of fearful memories. The drug is intended to inhibit the development of fear memory following a traumatic event.

Learn more about the technology and research status[CTO link: hyperlink to technology page]

Drug Market Potential
GlobalData estimates that the global PTSD therapeutics market was valued at $2.2 billion in 2010, and it is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% over the next seven years, to reach $2.9 billion by 2017.

According to the National Center for PTSD in USA about 7 out of every 100 people will experience PTSD at some point in their lives. The most studied medications for treating PTSD include antidepressants, which may help control PTSD symptoms.

Pep-EphrinA4 has the potential to serve as a first-in-class PTSD drug candidate to prevent some of the debilitating consequences of fear-related diseases such as PTSD.

IP Status
Patent pending (national phase)

Innovation Investment & Partnership Opportunities
MemoDero Ltd. received seed investment from the Carmel Innovations Fund, supporting the company’s research and development and steering it towards its present accomplishments.


Related Pages

Treating Fear and Stress Disorders

Rafi Lamprecht, Dr. - Researcher page


Carmel Ltd. is now seeking potential partners and/or investors to drive strong company growth and drug market disruption.

This email address is being protected from spambots. You need JavaScript enabled to view it.